@todayshow's FDA warning about Ozempic, fact-checked

What did @todayshow actually say?

The Today Show reported that the FDA issued a warning letter to Novo Nordisk for failing to report side effects from Ozempic and Wegovy within required timeframes. The core claim: three patient deaths, including one suicide, were not properly reported or investigated by the company. That is accurate and newsworthy.

The clip is short and mostly sticks to the facts of the warning letter itself. The anchor says Novo Nordisk "did not report the deaths within the agency's required timeframe" and "failed to investigate or report the suicide." Those claims match what the FDA's warning letter publicly stated. The segment ends with a brief company statement about working to address the FDA's concerns, which is fair balance for a 30-second news hit.

Does the science back this up?

The FDA's pharmacovigilance reporting requirements are real, enforceable, and not new. Companies are required under 21 CFR Part 314 to submit expedited reports of serious and unexpected adverse events, including deaths, within 15 days of becoming aware of them. Novo Nordisk apparently missed that window on multiple cases.

What the clip does not get into, and what matters clinically, is whether semaglutide itself caused these deaths. A warning letter about reporting failures is not the same as a finding of causation. The FDA has separately been monitoring GLP-1 receptor agonists for suicidal ideation signals since 2023, following the European Medicines Agency flagging similar concerns with liraglutide and semaglutide. A 2023 EMA review found no confirmed causal link, but the investigation remained open as of that review's publication. The pharmacovigilance system exists precisely because post-market safety signals are not always visible in clinical trials.

What did they get wrong (or right)?

Mostly right, with one significant omission. The reporting is factually accurate as far as it goes. But presenting three deaths in the context of millions of prescriptions, without any denominator, could leave viewers with a distorted sense of relative risk.

Ozempic and Wegovy together have been prescribed to tens of millions of patients globally. The warning letter is about regulatory compliance failures, not a new safety signal proving these drugs kill people. That distinction matters. A news clip that says "three deaths" without noting that the issue is a reporting timeline violation, not necessarily a drug-caused death cluster, is doing its audience a disservice. To be fair, the anchor does say "potential side effects" rather than confirmed harms, which is the right qualifier. But the framing still leans into alarm without providing the regulatory and statistical context a viewer would need to make sense of it.

What should you actually know?

If you are taking semaglutide, this warning letter is not a reason to stop your medication without talking to your doctor. The FDA issues warning letters for procedural violations all the time. What this case tells you is that Novo Nordisk did not follow its own reporting obligations, which is a compliance problem and a legitimate concern about corporate accountability, but it is not proof that Ozempic or Wegovy caused three deaths.

The more relevant ongoing question is whether GLP-1 receptor agonists have psychiatric side effects. The FDA added a review of suicidality signals to its 2023 safety agenda. A 2024 analysis published in Nature Medicine (Bezin et al., 2024) found no statistically significant increase in suicidal ideation with semaglutide compared to other diabetes medications. That does not close the question, but it provides more context than a 30-second clip can.

The FDA's pharmacovigilance system depends on manufacturers reporting adverse events honestly and on time. When they do not, the system breaks down. That is the real story here, and it is worth paying attention to regardless of what drug is involved.